ArticlePlacenta2025
A human cytotrophoblast-villous endothelium-fetal organ multi-cell model and the impact on gene and protein expression in placenta cytotrophoblast, fetal hepatocytes and fetal kidney epithelial cells.
Article in Placenta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
3 authors.
Funding
Abstract
introductionAppropriate fetal growth requires multi-directional, coordinated communication between maternal, placental, and fetal systems. Disruptions in these signaling arms can have deleterious consequences for fetal growth and lead to fetal developmental adaptations associated with short- and long-term morbidities. This proof-of-concept human cell model study aimed to identify the effects of altered trophoblast culture conditions and human insulin-like 1 growth factor (hIGF1) nanoparticle gene therapy on fetal liver hepatocytes and kidney epithelial cells.
methodsWe utilized human cell lines: BeWo choriocarcinoma cells (trophoblast), Human Placental Micro-Vascular Endothelial Cells, and WRL68 (hepatocytes) or HEK293T/17 (kidney epithelium), in a co-culture model designed to mimic cytotrophoblast-villous endothelium-fetal organ communication.
resultsTrophoblast stress response mechanisms were increased by culturing BeWo cells in growth media without fetal bovine serum (FBS). BeWo cells were also cultured without FBS and treated with a hIGF1 nanoparticle gene therapy which is known to mitigate cellular stress mechanisms. BeWo cells without FBS support had increased expression of cellular stress mechanisms but not when IGF1 was over-expressed with a transient hIGF1 nanoparticle gene therapy. BeWo cells without FBS and without FBS + hIGF1 nanoparticle gene therapy had increased expression of gluconeogenesis and glycolysis rate-limiting enzymes. Gene and protein expression in fetal liver and kidney cells was not impacted by increased trophoblast stress or hIGF1 nanoparticle gene therapy. DISCUSSION: Our data demonstrated that cytotrophoblast, cultured without FBS support, turn on mechanisms involved in glucose production. Whether this is reflected in vivo remains uninvestigated but may represent a placental compensation mechanism in complicated pregnancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.